You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 1 - 10 of 4256 results
  1. Innovative Continuous Sanitization of Fresh Produce Harvesting Equipment

    SBC: En Solucion Inc            Topic: FDA

    Recent foodborne illness outbreaks traced to contaminated field harvesting equipment have highlighted the need for incorporating improved sanitization practices at the time of harvest. Field- harvested specialty crops represent 50% of the top ten foods linked to major recalls and outbreaks over the past five years. Proper sanitization of outdoor harvest equipment is made complicated by operational ...

    SBIR Phase I 2023 Department of Health and Human ServicesFood and Drug Administration
  2. Geostatistical Software for Non-Parametric Geostatistical Modeling of Uncertainty

    SBC: BIO-ANALYTICS, INC.            Topic: NLM

    7. Project Summary/Abstract A key component in any investigation of association and/or cause-effect relationships between the environment and health outcomes is the availability of accurate and precise models of exposure. Because the cost of collecting field data is often prohibitive, it is critical to incorporate any source of secondary information available to supplement sparse datasets. Seconda ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. A Potent D-peptide Inhibitor of TNFα for Treatment of Rheumatoid Arthritis

    SBC: D BioTherapeutics, LLC            Topic: NIAMS

    Rheumatoid arthritis (RA) is a chronic, debilitating inflammatory disease with high medical and societal costs afflicting more than 1.6 million Americans. Blockade of TNFα-driven inflammation with approved anti-TNFα biologics (such as Humira®, Remicade®, Simponi®, and Enbrel®) is an effective treatment for many patients suffering from RA. However, due at least in part to the immunogenicity o ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. PET Imaging to Evaluate a Novel Chemokine Antagonist to Protect Synapses in ADRD

    SBC: CREATIVE BIO-PEPTIDES INC            Topic: NIA

    7. Project Summary ADRD dementias account for up to 25% of all dementias in patients older than 65 years and there is strong evidence of co-morbid pathologies caused by (amyloid β (Aβ), tau and α-synuclein (αSyn). The degree of AD- related pathology in Lewy Body Dementias (LBD) is moderate or severe in 50% of PDD and more than 70% of DLB patients have concomitant AD-related pathology so that t ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Modular Virtual Reality Therapeutic for Opioid and Stimulant Use Disorders

    SBC: INNATEVR LLC            Topic: NIDA

    PROJECT SUMMARY Opioid and/or Stimulant Use Disorders (OUD/StUD) are chronic, recurring conditions that if left untreated, pose a significant and ongoing public health and safety threat, with costs associated with OUD alone in the US exceeding one trillion dollars annually. Virtual Reality Cue Exposure (VRCE) employs safe and controlled repeated exposure to a variety of substance use cues and envi ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Development of a sample preparation protocol for 3D kidney ultrastructural analysis and immunolabeling by light microscopy

    SBC: panluminate Inc.            Topic: 400

    Abstract The success of cohort studies such as the NIDDK Kidney Precision Medicine Project (KPMP) with its massive amount of samples depends on the cost and time-efficient evaluation of kidney biopsies at multiple scales. Assessing the structure of kidney tissue at the nanoscale (~10 nm) and evaluating the 3-D distribution of protein biomarkers in that context is, however, currently severely limit ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Multisensory Augmented Reality as a bridge to audio-only accommodations for inclusive STEM interactive digital media

    SBC: ALCHEMIE SOLUTIONS, INC.            Topic: 500

    Only 3% of individuals who are blind or have low vision (BLV) have been employed in a STEM field. The lack of accessible accommodations to visually rich dynamic STEM content creates roadblocks to success for BLV students in STEM education throughout their academic journey. The goal of this SBIR is a usable system of accommodations for Interactive Digital Media (IDM), so students with profound visu ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  8. PANK Activators for the treatment of pantothenate kinase-associated neurodegeneration

    SBC: Virtus Therapeutics Corporation            Topic: NINDS

    SUMMARY Pantothenate kinase-associated neurodegeneration, PKAN, is a rare progressive neurodegenerative disorder associated with iron accumulation in the brain. The disease causes early immobility and often death by early adulthood. PKAN is caused by mutations in one of four human pantothenate kinase genes, PANK2 gene, which encodes a mitochondrial pantothenate kinase. Consistent with the clinical ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Treatment of status epilepticus and refractory status epilepticus with intravenous topiramate.

    SBC: PREVEP, LLC            Topic: NINDS

    Abstract Status epilepticus (SE) is a common neurologic emergency that fails to respond to first- and second-line anti-seizure medications (ASMs) in about one third of instances, thus progressing to refractory SE (RSE). Patients with RSE are at grave risk for neurological morbidity and mortality. The recently completed NIH-funded Established SE Treatment Trial (ESETT) highlights the need for impro ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Increasing IDeA state Biomedical Entrepreneurship via Ecosystem, Enterprises and Experts

    SBC: Insitehub LLC            Topic: NIGMS

    Summary The proposed DE iRED program consists of university and private sector partnerships to deliver a comprehensive program that will engage and support biomedical innovators in the early stages of technology commercialization by addressing key bottlenecks in the startup process as identified both in the solicitation and by the DRIVEN Accelerator Hub. According to DRIVEN’s Voice of Customer i ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government